Drug Trial Radar · NCT07050134
A Trial to Evaluate the Efficacy and Safety of DR10624 in Patients With Hypertriglyceridemia and Carotid Atherosclerotic Plaque
Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
40
Planned (sponsor's estimate)
Start
Jul 1, 2025
Primary completion
Dec 31, 2026
Study completion Jul 5, 2027
Sponsor
- Lead sponsor
- Junbo GeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Zhejiang Doer Biologics Co., Ltd.
- First posted
- Jul 3, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a researcher-initiated study to evaluate the effect of DR10624 injection on carotid atherosclerotic plaques in patients with hypertriglyceridemia and carotid atherosclerotic plaques. The study adopts a randomized, double-blind, placebo-controlled design. The treatment group has one dose group, with titration administration. The administration starts at 12.5 mg QW for 4 weeks, then titrates to 25 mg QW for 4 weeks, and finally to 50 mg QW for 16 weeks, totaling 24 administrations. The control group receives placebo treatment with the same volume and administration method as the treatment group. The study is divided into a screening period (3 weeks), a treatment period (24 weeks), and a follow-up period (4 weeks). Screening period (W-3 to W-1): Before participating in the screening, the subjects must fully understand all the risks and possible benefits of the trial and sign a written informed consent form voluntarily. Subjects entering the screening period will also receive therapeutic lifestyle guidance. Two fasting serum triglyceride tests are required during the screening period, with one test completed within one week before the first administration and an interval of at least one week between the two tests. On the day before the treatment period (D-1), eligible subjects will be randomly assigned and receive a randomization number. Treatment period (W0 to W24): Subjects who pass the screening will enter the treatment period and receive the target dose through titration. They will receive DR10624 injection at 12.5 mg QW or placebo QW for 4 weeks (W0 to W3), then at 25 mg QW or placebo QW for 4 weeks (W4 to W7), and finally at 50 mg QW or placebo QW for 16 weeks (W8 to W23), totaling 24 administrations over 24 weeks. Subjects need to return to the research center weekly for drug administration during W0 to W23. After each administration, injection site observations are required (30 minutes (±10 minutes) and 1 hour (±10 minutes) after each administration to check for injection site reactions), and corresponding efficacy and safety evaluations are completed as per the visit schedule. The last administration is on D162, and the end of treatment is defined as one week after the last administration (W24, D169). All subjects will return to the research center on D169 for the last efficacy and safety evaluations during the treatment period. Safety follow-up period (W25 to W28): All subjects who complete the treatment will enter a 4-week safety follow-up period. The final visit is on D197, and all subjects will return to the research center on D197 for the final assessment of this study.
Conditions
- Hypertriglyceridemia
- Carotid Atherosclerotic Plaques
Interventions
DR10624 Injection;Drug
The experimental group(Trial Drug) * Name: DR10624 Injection (referred to as DR10624) * Specification: 60mg (1mL)/vial * Active Ingredient: DR10624 * Route of Administration: Subcutaneous injection * Packaging: Vial * Expiry Date: See the drug label * Storage Conditions: 2\~8℃, protected from light * Manufacturer: Zhixiang Bio (Suzhou) Co., Ltd. * Supplier: Zhejiang Daor Biotechnology Co., Ltd.
DR10624 Injection Placebo (referred to as placebo)Drug
(The control group)Placebo: Name: DR10624 Injection Placebo (referred to as placebo) Specification: 0mg (1mL)/vial (no active ingredient) Main Component: Normal saline Route of Administration: Subcutaneous injection Packaging: Vial Expiry Date: See the drug label Storage Conditions: 2\~8℃, protected from light Manufacturer: Zhixiang Bio (Suzhou) Co., Ltd. Supplier: Zhejiang Daor Biotechnology Co., Ltd.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in carotid intima-media thickness (IMT) from baseline at treatment week 24 (W24).Time frame: 24weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Anhui Medicaluniversity
Hefei, Anhui, China
Suzhou Municipal Hospital
Suzhou, Jiangsu, China
The Central Hospital of Xuhui District
Shanghai, Shanghai Municipality, China
Zhongshan Hospital Affiliated with Fudan University
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.